The launch of Chr. Hansen YoFlex® Acidifix™ culture opens for new cost-saving yogurt technology
“I believe that this is the future way of making yogurt”, Karsten Tjener, Marketing Director Fresh Dairy, Chr. Hansen.
“I believe that this is the future way of making yogurt”, Karsten Tjener, Marketing Director Fresh Dairy, Chr. Hansen.
Millions of people around the world suffer from a range of gastrointestinal symptoms. Results from one of the world’s largest clinical studies on probiotics now show that the probiotic strain named BB-12® can be part of the solution by improving bowel regularity.
Chr. Hansen realizes strong organic growth of 9% in the first nine months of 2014/15, narrows organic revenue expectations to 8-9% and declares interim dividend to shareholders.
In collaboration with University of Copenhagen, Department of Plant and Environmental Sciences (KU) and Technical University of Denmark, Department of Systems Biology (DTU), researchers from Chr. Hansen have succeeded in producing carmine by a modern fermentation process. The first of a series of patents that protects the technology has been published today.
With the launch of Chr. Hansen’s DVS®WhiteClassic culture, producers of both classic Feta and non-PDO Feta can access the classic flavour and texture that consumers are looking for.
Jesper Allentoft has been with Chr. Hansen since 1 January, 2006 and is now retiring early at the age of 60. Ditte Marstrand Wulf will start as Group Vice President, Stakeholder Relations on 1 August, 2015.
With the completion and publication of the world’s largest clinical study on the immune effect of probiotics in adults, Chr. Hansen has obtained results indicating that the probiotic strain named L. CASEI 431® can shorten the duration of common cold and influenza-like illness, lower the use of health care resources and reduce use of antibiotics.
A study initiated by Chr. Hansen has shown that bifidobacteria and lactobacilli are present in breast milk from Chinese mothers, strengthening the case for adding clinically documented probiotics to infant formula, in order to improve nutrition.
The market for natural dietary supplements is booming and Chr. Hansen will present its growing portfolio of products at this year’s Vitafoods Europe, with focus on the ground-breaking technology LIFE GEL®, and the award-nominated product solution Mother’s 1st.
Establishes a new research and development consortium and secures access and commercialization rights to an important resource of strains
Strong organic revenue growth of 11% in the first half of 2014/15
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
Boege Allé 10-12
DK-2970 Hoersholm
Denmark